Promising Treatment: Jasper Therapeutics Unveils Briquilimab Data at EAACI 2024

Introduction

Jasper Therapeutics, a clinical-stage biotech company, is excited to present new data on briquilimab, a novel antibody therapy, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

Key Findings in Asthma Research

Recent studies demonstrated that a single dose of briquilimab can significantly deplete mast cells in inflamed and non-inflamed lung tissues. This depletion improved lung function in an allergen-induced asthma model, highlighting briquilimab's potential in asthma treatment.

These findings used Jasper's proprietary c-Kit Mouse™, a model that adeptly binds human c-Kit receptor antibodies, overcoming limitations of previous models.

Briquilimab and Atopic Dermatitis (AD)

The preclinical AD study showcased a reduction in dermal mast cells and inflammatory leukocytes following briquilimab treatment. This indicates that mast cells are crucial in AD pathogenesis and that briquilimab might reverse AD by targeting these cells.

Healthy Volunteer Studies

Data from healthy volunteers further reinforce briquilimab's safety. The clinical trial demonstrated that the antibody is well-tolerated, showing a favorable pharmacokinetic (PK) profile. It also revealed sustained, dose-dependent depletion of mast cells.

BEACON and SPOTLIGHT Trials

Data from the BEACON and SPOTLIGHT clinical studies show promising results in treating chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Studied participants displayed significant symptom improvement, promoting the potential of briquilimab in these conditions.

Further Research Directions

With these promising results, Jasper plans to further explore briquilimab in various mast cell diseases. Upcoming Phase 1b/2a trials will focus on broader applications, starting with a planned challenge study in asthma by late 2024.

About Briquilimab

Briquilimab is a targeted monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor (CD117). This interruption leads to mast cell depletion, addressing the root of inflammation in mast cell-driven diseases like chronic urticaria and asthma.

Safety and Efficacy

To date, over 145 participants have received briquilimab, demonstrating its safety and efficacy as a therapeutic agent. Notably, it has been effective as a conditioning agent in cell therapies for rare diseases, adding to its potential impact in clinical settings.

Conclusion

Jasper Therapeutics continues to advance briquilimab as a significant treatment option for various mast cell diseases. The breadth of research presented at EAACI 2024 underscores its potential as a versatile therapeutic agent.

Future Prospects

Jasper looks forward to expanding the clinical application of briquilimab and is optimistic about its potential to improve outcomes for patients with CSU, CIndU, asthma, and beyond.